A Phase 4 interventional study of Stalevo (levodopa/carbidopa/entacapone) and Levodopa/carbidopa in Idiopathic Parkinson's Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 19 sites in 6 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2009-06-22.
Sponsored by Orion Corporation, Orion Pharma · Phase 4, Interventional, and Treatment
The purpose of this study is to demonstrate in patients with Parkinson's disease that, when compared to levodopa/carbidopa, Stalevo will delay the time from initiation of study drug to the time an increase in antiparkinsonian medication is required due to inadequately controlled parkinsonian symptoms.
4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.
This study's enrollment of 223 is above the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Orion Corporation, Orion Pharma is the lead sponsor of 100 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Stalevo (levodopa/carbidopa/entacapone)
Drug: Stalevo (levodopa/carbidopa/entacapone)
Levodopa/carbidopa
Drug: Levodopa/carbidopa
Oral, 50-150 mg levodopa four times daily, for up to 2 years
Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
The time until a patient requires changes in antiparkinsonian therapy due to inadequately controlled parkinsonian symptoms
Time frame: Up to 2 years of treatment
Unified Parkinson's Disease Rating Scale
Time frame: Up to 2 years of treatment
Clinical Global Impression of Change (investigator)
Time frame: Up to 2 years of treatment
Parkinson's Disease Questionnaire (PDQ-39)
Time frame: Up to 2 years of treatment
Work Impairment Questionnaire
Time frame: Up to 2 years of treatment
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Orion Corporation, Orion Pharma